These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19601472)

  • 41. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
    Ali TZ; Epstein JI
    Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytokeratin (AE1/AE3) in addition to alpha-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma.
    Raspollini MR
    Hum Pathol; 2008 Feb; 39(2):304-5; author reply 305-6. PubMed ID: 18206500
    [No Abstract]   [Full Text] [Related]  

  • 43. [Skin metastases in prostatic cancer. Immunohistologic indications of the primary tumor].
    Schoel J; Smolle J; Kerl H
    Hautarzt; 1989 Jan; 40(1):34-6. PubMed ID: 2466019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ductal ("endometrioid") adenocarcinoma of the prostate.
    Colpaert C; Gentens P; Van Marck E
    Acta Urol Belg; 1998 Dec; 66(4):29-32. PubMed ID: 10083631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining.
    Weinbreck N; Marie B; Bressenot A; Montagne K; Joud A; Baumann C; Klein O; Vignaud JM
    Am J Surg Pathol; 2008 Jul; 32(7):1051-9. PubMed ID: 18496143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenocarcinomas of the prostatic duct in necropsy material.
    Stamatiou K; Alevizos A; Mariolis A; Fanou D; Alevizou A; Michalodimitrakis E; Sofras F
    Can J Urol; 2007 Apr; 14(2):3502-6. PubMed ID: 17466156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features.
    Seipel AH; Delahunt B; Samaratunga H; Egevad L
    Pathology; 2016 Aug; 48(5):398-405. PubMed ID: 27321992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Calcifications in prostate and ejaculatory system: a study on 298 consecutive whole mount sections of prostate from radical prostatectomy or cystoprostatectomy specimens.
    Suh JH; Gardner JM; Kee KH; Shen S; Ayala AG; Ro JY
    Ann Diagn Pathol; 2008 Jun; 12(3):165-70. PubMed ID: 18486891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary ductal adenocarcinoma of the lacrimal gland.
    Milman T; Shields JA; Husson M; Marr BP; Shields CL; Eagle RC
    Ophthalmology; 2005 Nov; 112(11):2048-51. PubMed ID: 16271319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravesical botryoid adenocarcinoma of the prostate: report of an unusual growth pattern of prostatic carcinoma simulating a urinary bladder tumor.
    Camilot D; Pizzolitto S; DeMaglio G; Falconieri G
    Ann Diagn Pathol; 2007 Dec; 11(6):413-6. PubMed ID: 18022125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostatic stromal sarcoma in a young adult: a case report.
    Chang YS; Chuang CK; Ng KF; Liao SK
    Arch Androl; 2005; 51(6):419-24. PubMed ID: 16214726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secondary colonic adenocarcinoma of the prostate histologically mimicking prostatic ductal adenocarcinoma.
    Mai KT; Landry DC; Collins JP
    Tumori; 2002; 88(4):341-4. PubMed ID: 12400988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation.
    Kawahara A; Harada H; Akiba J; Kage M
    Diagn Cytopathol; 2008 Jul; 36(7):485-93. PubMed ID: 18528886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case of prostatic duct adenocarcinoma: its clinical significance in comparison with typical acinar adenocarcinoma.
    Takazawa R; Kawakami S; Yamamoto K; Kubo Y; Kageyama Y; Kihara K
    Hinyokika Kiyo; 2008 Mar; 54(3):243-7. PubMed ID: 18411784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Salivary duct carcinoma in the submandibular region.
    Toyoda H; Yamaguchi K; Miura K; Fukuda H; Hashimoto K
    Int J Oral Maxillofac Surg; 2003 Aug; 32(4):427-9. PubMed ID: 14505630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cylindroma of the prostate.
    Bauer R
    Am J Surg Pathol; 2007 Aug; 31(8):1288-91. PubMed ID: 17667556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Large cystic ductal carcinoma of the prostate: imaging findings and minimally invasive surgical treatment.
    Torricelli FC; Tucherman M; Melogno R; Coelho RF
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432907
    [No Abstract]   [Full Text] [Related]  

  • 59. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer.
    Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA
    Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemical markers in the diagnosis of prostate cancer.
    Fleshman RL; MacLennan GT
    J Urol; 2005 May; 173(5):1759. PubMed ID: 15821581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.